Minimal residual disease (MRD) is one of the most relevant prognostic factors in patients with multiple myeloma (MM); however, the impact of maintenance therapy on MRD levels remains unclear. Among patients with newly diagnosed MM (NDMM) who received lenalidomide maintenance until they developed disease progression, the role of MRD status as a predictor of progression-free survival (PFS) was evaluated by multiparameter flow cytometry (MFC) and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction (ASO-RQ-PCR) analysis. METHODS: Seventy-three patients with NDMM enrolled in the RV-MM-EMN-441 (clinical trials.gov identifier, NCT01091831) and RV-MM-COOP-0556 (clinicaltrials.gov identifier, NCT01208766; European Myeloma Network EMN02/HO95 MM Trial) phase 3 trials who achieved at least a very good partial response after intensification/consolidation were included. The median patient age was 57 years (interquartile range, 53-61 years), and all patients received lenalidomide maintenance until they developed progression. MRD was evaluated on bone marrow after intensification/consolidation, after 6 courses of maintenance, and every 6 months thereafter until clinical relapse using both ASO-RQ-PCR (sensitivity, 10 −5 ) and MFC (sensitivity, from 10 −4 to 10 −5 ).
INTRODUCTION
Multiple myeloma (MM) is a plasma cell malignancy, and its outcome has improved markedly during the last 10 to 15 years thanks to the introduction of novel agents and autologous stem cell transplantation (ASCT). Recently, consolidation and maintenance therapy increased the rates and depth of response. 1, 2 Because most patients who attain a complete response (CR) ultimately relapse, more sensitive methods are needed to detect and quantify minimal residual disease (MRD). Several techniques have been explored, such as quantitative allelic-specific oligonucleotide real-time
Cancer March 1, 2019 quantitative polymerase chain reaction (ASO-RQ-PCR) analysis and high-throughput, next-generation sequencing (NGS) for molecular response evaluation; and multiparameter flow cytometry (MFC) and next-generation flow (NGF) to evaluate bone marrow (BM) plasma cell residual disease. The lower MRD level attained with the higher sensitivity technique, the longer the progression-free survival (PFS). 3 A recent meta-analysis demonstrated an advantage for MRD-negative versus MRD-positive patients. In particular, among patients who achieved a conventional CR, MRD results were reported in 5 studies for PFS [4] [5] [6] [7] [8] and in 6 studies for overall survival (OS).
4-10 MRD-negative patients had a significantly better PFS (hazard ratio [HR] , 0.44; P < .0001) and OS (HR, 0.47; P < .0001) compared with MRDpositive patients. Moreover, 5 studies evaluated MRD before and after ASCT and indicated that the proportions of patients who achieved negative MRD status increased after ASCT. [11] [12] [13] [14] [15] Similarly, 2 studies reported that maintenance therapy increased the proportion of patients who achieved and maintained MRD-negative status. 11, 12 That meta-analysis also demonstrated that patients with favorable cytogenetic profiles who achieved MRD-negative status had the best OS; conversely, patients with high-risk cytogenetic profiles who remained positive for MRD had the worst outcome. In the current study, we evaluated MRD using ASO-RQ-PCR and MFC analyses in patients who received bortezomib-based or lenalidomide-based, front-line induction followed by ASCT or no-ASCT consolidation and started lenalidomide maintenance. A pooled analysis was performed because of the suitable number of patients enrolled in whom MRD levels had been recorded at different time points during lenalidomide maintenance.
MATERIALS AND METHODS

Patients and Study Design
We pooled 105 patients with newly diagnosed MM (NDMM) who were enrolled in 2 phase 3 clinical trials: RV-MM-EMN-441 (clinicaltrials.gov identifier, NCT01091831) 16 and RV-MM-COOP-0556 (clinicaltrials.gov identifier, NCT01208766; European Myeloma Network EMN02/HO95 MM Trial). 17 The 2 study designs are illustrated in the Supporting Information (Supporting Fig. 1 ). In the RV-MM-EMN-441 study, patients were randomized at enrollment at a 1:1:1:1 ratio either to receive consolidation with 6 cycles of combined cyclophosphamide, lenalidomide, and dexamethasone (CRD) or to undergo melphalan-conditioned ASCT and to receive maintenance either with lenalidomide or with lenalidomide plus prednisone until they had a relapse or developed intolerance. Patients received 4 cycles of lenalidomide plus dexamethasone (RD) induction, followed by mobilization, then stem cell collection. Subsequently, when eligibility for consolidation was confirmed, the patient's treatment allocation was disclosed. In the RV-MM-COOP-0556 trial, patients received 3 or 4 cycles of combined bortezomib, cyclophosphamide, and dexamethasone (VCD) induction, followed by mobilization, and then stem cell collection. Next, patients were randomized to receive either 4 cycles of combined bortezomib, melphalan, and prednisone (VMP) or 1 or 2 cycles of high-dose melphalan followed by ASCT. After intensification, patients were randomized secondarily to receive either 2 cycles of combined bortezomib, lenalidomide, and dexamethasone as consolidation or no consolidation, followed by lenalidomide maintenance in both arms until they developed progression or intolerance. Response to treatment was assessed according to International Myeloma Working Group criteria. 18 Patients who achieved at least a very good partial response (VGPR) after intensification/consolidation and had plasma cell infiltration ≥5% at baseline were eligible for the MRD substudy. This cutoff was chosen because of the technical issues in obtaining the molecular marker in patients who had a lower plasma cell infiltration at baseline. MRD analysis was performed on BM aspirates collected at different time points: after intensification/ consolidation, after 6 courses of maintenance, and every 6 months thereafter until patients had a clinical relapse. The MRD substudy was conducted in accordance with the Declaration of Helsinki principles and was approved by the relevant institutional review boards. Written informed consent was obtained from all patients.
MRD Assessment by MFC
MFC assays were performed on BM aspirates centralized to a single laboratory (Laboratory of Cytofluorimetry, University of Turin, Turin, Italy). BM processing was done within 24 to 48 hours after collection according to the EuroFlow guidelines. 19, 20 In the RV-MM-EMN-441 trial, MRD was investigated using either of 2 tubes with 6 colors (tube 1 CD19-PerCp-Cy5.5, CD56-APC, CD45-APC-H7, and CD38-PE-Cy7). Acquisition and analyses were performed using a FACSCanto II flow cytometer equipped with FACSDiva software (BD Biosciences, San Jose, CA), and we acquired a minimum of 1 × 10 6 events for each sample. In the RV-MM-COOP-0556 trial, we switched to a panel of 2 tubes with 8 colors (tube 1: CD81F, CD27-PE, CD138-PC5.5, CD19-PE-Cy7, CD20-APC, CD38-Pacific Blue [PB] , and CD45-Krome Orange [KO]; tube 2: cyKappa-FITC/cyLambda-PE, CD138-PC5.5, CD19-PE-Cy7, CD56-APC, CD117-APC-A750, CD38-PB, and CD45-KO); acquisition and analyses were performed using a NAvios flow cytometer equipped with Kaluza software (Beckman Coulter, Brea, CA), and we acquired a minimum of 2 × 10 6 events for each sample. Flow-CR was defined as the detection of <20 clonal plasma cells among ≥200,000 nucleated cells at a sensitivity level from 10 −4 to 10 −5 in 2 consecutive evaluations.
MRD Assessment by ASO-RQ-PCR
Genomic DNA from BM samples was isolated using DNAzol reagent (Life Technologies-Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Patient-specific immunoglobulin heavy chain rearrangements were amplified and directly sequenced from genomic DNA at diagnosis, 21 the sequences were analyzed using the International Immunogenetics Information System (IMGT)/V-QUEST tool (available at: https:// www.imgt.org, Accessed October 29, 2018), 22, 23 and patient-specific ASO primers and consensus probes were designed as previously described. 21 Immunoglobulin heavy chain-based MRD detection by ASO-RQ-PCR was performed using an AbiPrism7900HT (Life Technologies-Applied Biosystems) and MRD analyses were interpreted according to the EuroMRD guidelines. 24 A molecular CR (m-CR) was defined as 2 consecutive negative MRD results by ASO-RQ-PCR with minimal sensitivity of 10 −5 . The molecular MRD kinetics analysis was performed using the observed marginal mean natural logarithm (ln) PCR value.
Cytogenetic Characterization
Fluorescence in situ hybridization (FISH) was performed on purified CD138-positive cells obtained from BM at diagnosis according to standard procedure. Patients were divided in 2 groups according to their FISH profile: high-risk patients with at least 1 of a del17p13 deletion or a t(4;14) or t(14;16) translocation and standard-risk patients without any of these chromosomal abnormalities. When such data were not available, patients were included in the missing data category.
Statistical Analysis
Data from the 2 trials were pooled together and analyzed. The MRD population was defined as patients who had an available MRD sample before and/or after starting maintenance. PFS was calculated from the date of BM sampling before maintenance to the date of progression or death or the date the patient was last known to be in remission. OS was calculated from the date of BM sampling before maintenance to the date of death or the date the patient was last known to be alive. Time-to-event data were analyzed using the Kaplan-Meier method, and the log-rank test was used to compare curves. Multivariate Cox proportional-hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for MRD status, sex, age, International Staging System (ISS), cytogenetic risk, and intensification/consolidation therapy (ASCT or no ASCT). Subgroup analyses were performed to determine the consistency of effects of negative versus positive MRD status in the different subgroups using interaction terms between MRD status and each of the covariates included in the Cox model. All HRs were estimated with their 95% CIs, and 2-sided p-values. The Pearson correlation coefficient (r) was used to compare methods of MRD analysis (ASO-RQ-PCR and MFC). Data were analyzed as of December 2017 using R (version 3.1.1; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient Characteristics and MRD After Intensification/Consolidation
Overall, 105 patients who achieved at least a VGPR and who had BM plasma cell infiltration ≥5% at baseline were enrolled in the MRD substudy. In total 73 patients (70%) could be analyzed, and 32 (30%) could not be analyzed because of unsuccessful sequencing or lack of clonality (Supporting Fig. 2 ). The median patient age was 57 years (interquartile range, 53-61 years), 10 (14%) had ISS stage III disease, and 24 (33%) had highrisk cytogenetic profile (Table 1) . Thirty-five patients received ASCT intensification/consolidation (40% achieved a VGPR, and 60% attained a CR or a stringent CR), whereas 38 did not (39% achieved a VGPR, and 61% achieved a CR or a stringent CR).
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All 73 patients started maintenance with lenalidomide. The achievement of negative MRD status after intensification/consolidation significantly improved PFS according to both ASO-RQ-PCR results (median PFS, not reached vs 37.1 months for negative vs positive MRD status, respectively; P = .01) and MFC results (median PFS, not reached vs 26 months for negative vs positive MRD status, respectively; P = .002).
MRD Status During Maintenance
At the time of data cutoff, the median duration of maintenance was 29.1 months (interquartile range, 16.4-40.4 months), and 9 patients had discontinued therapy because of adverse events, including a second cancer (Supporting Fig. 2 ). Lenalidomide maintenance therapy further improved the rates of MRD negativity: among MRD-positive patients after intensification/consolidation, 12 of 39 patients (31%) obtained an m-CR, and 6 of 26 (23%) obtained a flow-CR during maintenance. The higher MRD-negative rate in the first group could explain in part the better PFS obtained by MRD-positive patients by ASO-RQ-PCR after intensification/consolidation compared with those who were MRD-positive by MFC.
In particular, there were 9 m-CRs (4 after ASCT and 5 after CRD or VMP) and 5 flow-CRs (2 after ASCT and 3 after CRD or VMP) after 6 months from the start of maintenance, 1 flow-CR after 18 months, 2 m-CRs after 18 months, and 1 m-CR after 24 months. Both ASO-RQ-PCR and MFC revealed that the achievement of negative MRD status during maintenance significantly improved PFS in all patients. The median PFS was not reached with either technique versus 26 months for persistently MRD-positive patients by ASO-RQ-PCR (P < .001) and 19.5 months for persistently MRDpositive patients by MFC (P < .001) (Fig. 1) . Compared with baseline prognostic factors for MM in a Cox model for PFS, negative MRD status was the most significant factor to reduce the risk of progression or death using both methods (ASO-RQ-PCR: HR, 0.29; 95% CI, 0.14-0.62; P = .001; MFC: HR, 0.19; 95% CI, 0.09-0.41; P < .001) (Fig. 2) .
In subgroup analyses, among MRD-negative patients, PFS was similar between the ASCT and no-ASCT groups and between those with ISS stage I versus stage II/III disease (Fig. 3) . It is noteworthy that MRD-negative patients who had high-risk cytogenetic profiles had a longer PFS (median, not reached by either ASO-RQ-PCR or MFC) versus MRD-positive patients (median, 22.6 months by ASO-RQ-PCR and 15.4 months by MFC) (Fig. 4) . Both methods of MRD assessment revealed significantly prolonged OS for all MRD-negative patients, with a 4-year OS rate of 84% and 80% in ASO-RQ-PCR and MFC MRD-negative patients, respectively, compared with 60% and 61% in ASO-RQ-PCR and MFC MRD-positive patients, respectively (P = .02 and P = .06, respectively) (Fig. 5) .
Moreover, patients who had persistent negative MRD status during maintenance had the best outcomes compared with those who became MRD-positive during maintenance or were MRD-positive during the whole treatment ( Supporting Fig. 4) . Indeed, as previously reported, 25 we identified 3 groups of patients with different molecular MRD kinetic patterns: 1) Thirty-seven patients exhibited a persistent MRD response (51%) and achieved a long-lasting m-CR until 36 months of maintenance, with a median tumor burden reduction of 10 ln-PCR. In this group, only 7 patients (19%) relapsed. 2) Fourteen patients experienced a transient MRD response (19%) and achieved an initial MRD response, with a median tumor burden reduction of 8 ln-PCR Nevertheless, Cancer March 1, 2019 MRD subsequently reappeared, with a median increase of 4 ln-PCR. In this group, 9 patients relapsed (64%).
3) Twenty-two patients had a minimal MRD response (30%), with a median tumor burden reduction of 5 ln-PCR. In this group, 15 patients (68%) progressed. The same trend was observed in the MFC analysis (Supporting Fig. 5 ). Finally, MRD relapse anticipated myeloma progression by a median of 8 to 9 months; 3 patients experienced extramedullary relapse, and only 1 of those 3 was previously MRD-positive. 26 
Comparison of MFC and ASO-RQ-PCR Analyses
Overall, the MFC and ASO-RQ-PCR methods had a highly significant level of concordance for MRD analysis (r = 0.9; P < .001) (Fig. 6 ). In total, 317 samples were analyzed for MRD detection by both MFC and ASO-RQ-PCR. The 2 methods were concordant in 285 analyses (90%); both methods produced MRD-positive results in 34% of analyses and MRD-negative results in 56% of analyses. Discordance between the 2 methods was observed in 32 paired samples (10%). In particular, 27 of 203 MFC-negative samples (13%) were PCR-positive, whereas 5 of 114 MFC-positive samples (4%) were PCR-negative.
DISCUSSION
The depth of response is one of the most relevant clinical prognostic factors in patients with MM. Thanks to effective drug combinations and the positive results obtained with immunotherapy, deeper responses (CR) can now be achieved. Therefore, physicians are redefining the goal of therapy, focusing on long-term control, quality of life, and even a cure. 27 MRD analysis is a valid tool to better characterize response. Here, we assessed MRD by both ASO-RQ-PCR and MFC assays in patients with NDMM who were eligible for high-dose therapy and received intensification/consolidation with bortezomib-based and lenalidomide-based strategies after front-line induction, followed by lenalidomide maintenance. In a previous report 26 on a small cohort from the RV-MM-EMN-441 study, we observed a significant impact of MRD on PFS. However, a correlation between the molecular and immunophenotypic techniques was not possible because of the small number of patients who had detectable molecular markers. In this pooled analysis, we evaluated both techniques in a larger series, and both methods confirmed the significant impact of MRD on PFS (ASO-RQ-PCR analysis: HR, 0.29; P = .001; MFC: HR, 0.19; P < .001). It is worth noting that sensitivity was slightly higher for ASO-RQ-PCR (10   −5 ); however, when we moved from a 6-color to a second-generation flow technique in the majority of our samples (73%), we observed an improvement in the level of MRD sensitivity by MFC (from 10 −4 to 10 −5 ). In line with other studies, 28, 29 we observed a high correlation between the 2 MRD techniques (r = 0.9; P < .001) and discordances in only 10% of paired samples.
In addition, ASO-RQ-PCR was applicable in only 70% of samples (excluding samples with <5% BM plasma cells), because of a lack of clonality and unsuccessful sequencing; whereas MFC exhibited 97% feasibility (9 of 327 samples were not evaluable because of low quality or hemodilution). Discordant results could be because of the half-life of M-components, BM plasma cells. 5 Moreover, discordances could be attributed to different sensitivity and the different targets analyzed. The newer techniques (NGS, NGF) can overcome these limits and are now accepted as standardized MRD assessment procedures. Moreover, the use of functional whole-body imaging techniques, such as positron emission tomography/computed tomography [PET/CT], has highlighted the problem of spatial heterogeneity, 30 with negative BM analysis results but the presence of skeletal lesions or extramedullary disease. Indeed, we missed 2 of 3 extramedullary relapses by evaluating the BM compartment only. Therefore, these techniques may be considered complementary along with sensitive immunophenotypic and molecular-based assays. Attempts to standardize the interpretation of results are ongoing. 31 Novel emerging technologies are evaluating the possibility to explore MRD in peripheral blood circulating tumor cells or by ultra-deep sequencing of cell-free DNA. Nevertheless, these methods can help to explore the mutational profile and subclonal composition of MM cells rather than detecting MRD because of the potential lack of sensitivity in peripheral blood after treatment. [32] [33] [34] We confirmed that MRD negativity is a strong prognostic factor in patients with MM, together with baseline clinical and biologic characteristics (ISS stage, cytogenetic risk, therapy). It is noteworthy that MRD-negative patients with high-risk cytogenetics had prolonged PFS (median, not reached by either ASO-RQ-PCR or MFC) versus MRD-positive patients (median, 22.6 months by ASO-RQ-PCR, 15.4 months by MFC). This observation is in line with data from a Spanish study in which the presence of baseline high-risk cytogenetic features and persistent MRD at day 100 after transplantation were associated with early relapse. 6 This is a very high-risk patient population, and early intervention is mandatory, although the achievement of m-CR or flow-CR can overcome the poor outcome of patients who have high-risk cytogenetics.
One of the limitations of the current pooled analysis was the relatively small sample size, which limited the multivariate and subgroup analyses. Indeed, in our Cox model, the impact of cytogenetics-along with other, well known prognostic factors for MM-was not as significant as expected. Moreover, another aspect that affected the number of patients in the subgroup analysis was that many high-risk patients may not have reached the first MRD assessment point. Finally, another limitation was that we could not analyze the overall population of the 2 studies at the completion of consolidation, because we did not assess all those who attained a VGPR or better using both techniques. It was consequently impossible to perform an intention-to-treat analysis by considering the missing patients as positive (there would be a chance of mistakenly including many patients who achieved a CR or a VGPR without an MRD assessment). MRD status may help define the success of a treatment and is a valid tool with which to compare different strategies, particularly in randomized trials.
Here, we have demonstrated that higher MRDnegative rates are achieved in the transplantation arms (56% and 67% by ASO-RQ-PCR and MFC, respectively) versus no transplantation (37% and 59% by ASO-RQ-PCR and MFC, respectively); both source studies demonstrated a superior outcome with high-dose therapy versus CRD or VMP intensification. 16, 17 Consistently, in the French Myeloma Intergroup (IFM)/Dana Farber Cancer Institute (DFCI) study, more patients achieved MRD negativity in the transplantation arm, and there was no difference in PFS among patients who achieved negative MRD status according to treatment arm. 35, 36 Similar results were reported in the Medical Research Council (MRC) study comparing conventional chemotherapy versus immunomodulatory drugs before transplantation: although more patients in that trial achieved MRD negativity with immunomodulatory-based induction, no survival differences were observed according to the type of induction. 37 Therefore, choosing a regimen that increases the chance of achieving MRD negativity is crucial. CASTOR and POLLUX studies investigated the addition of daratumumab to RD or VD in patients with relapsed/refractory MM and confirmed the better outcome of MRD-negative patients, regardless of previous therapies (daratumumab-VD or RD vs VD or RD alone), although the experimental arms led to higher rates of MRD negativity. [38] [39] [40] We have demonstrated that continuous treatment with lenalidomide can further improve the quality of response or maintain it over time, suggesting that both MRD negativity and continuous therapy may be important in long-term outcome. In our current analysis, almost one-third of MRD-positive patients became MRDnegative during maintenance treatment, and this result is substantially similar to the one obtained by Rawstron et al. in their analysis on thalidomide maintenance. 11 We note that only a prospective study analyzing maintenance versus no maintenance could really confirm these data, because a delayed response to consolidation/intensification may blind the authentic maintenance response, especially because most responses were obtained in the first 6 months. Finally, based on these data, we could speculate that, the earlier MRD negativity is achieved, the better the outcome, especially if it is persistent during the entire course of treatment.
Future randomized clinical trials based on MRD status at different time points will confirm such important results and will establish the role of delayed transplantation, consolidation versus no consolidation, and the length of maintenance after front-line therapy.
